Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens
Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens. During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin,...
Saved in:
Published in | Cancer chemotherapy and pharmacology Vol. 46; no. 2; pp. 119 - 127 |
---|---|
Main Authors | , , , , |
Format | Journal Article |
Language | English |
Published |
Berlin
Springer
2000
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Abstract | Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens. During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin, a sharp decrease in 4-hydroxycyclophosphamide concentration was observed immediately after the start of the thioTEPA infusion. A drug-drug interaction was suspected. This putative interaction was investigated in this study.
Possible sequence dependency, due to inhibition of the formation of 4-hydroxycyclophosphamide by thioTEPA, was investigated by altering the sequence of infusion in three patients (four courses) receiving high-dose chemotherapy with cyclophosphamide (1,000 or 1,500 mg/m2 per day), thioTEPA (80 or 120 mg/m2 per day) and carboplatin (265 or 400 mg/m2 per day) in short infusions for four consecutive days. The pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide were established. Possible inhibition of the metabolism of cyclophosphamide and thioTEPA was investigated in human microsomes.
A striking sequence dependency of the pharmacokinetics of 4-hydroxycyclophosphamide was observed. Administration of thioTEPA 1 h prior to cyclophosphamide resulted in decreased Cmax (-62%) and AUC (-26%) values of 4-hydroxycyclophosphamide compared to those of thioTEPA administered 1 h after cyclophosphamide. In human microsomes an inhibition of the conversion of cyclophosphamide to 4-hydroxycyclophosphamide by thioTEPA was observed at clinically relevant concentrations with an IC50 of 23 microM. No inhibition of the formation of TEPA by cyclophosphamide was observed.
ThioTEPA strongly inhibits the bioactivation of cyclophosphamide and this may decrease both efficacy and toxicity. Our results seriously question the practice of the simultaneous continuous infusion of cyclophosphamide and thioTEPA and suggest that the sequencing and scheduling of these two agents in high-dose chemotherapy regimens may be of critical importance. |
---|---|
AbstractList | Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens. During a pharmacokinetic study of 31 courses in 20 patients of cyclophosphamide and its activated metabolite 4-hydroxycyclophosphamide given in the combination cyclophosphamide thioTEPA carboplatin, a sharp decrease in 4-hydroxycyclophosphamide concentration was observed immediately after the start of the thioTEPA infusion. A drug-drug interaction was suspected. This putative interaction was investigated in this study.
Possible sequence dependency, due to inhibition of the formation of 4-hydroxycyclophosphamide by thioTEPA, was investigated by altering the sequence of infusion in three patients (four courses) receiving high-dose chemotherapy with cyclophosphamide (1,000 or 1,500 mg/m2 per day), thioTEPA (80 or 120 mg/m2 per day) and carboplatin (265 or 400 mg/m2 per day) in short infusions for four consecutive days. The pharmacokinetics of cyclophosphamide and 4-hydroxycyclophosphamide were established. Possible inhibition of the metabolism of cyclophosphamide and thioTEPA was investigated in human microsomes.
A striking sequence dependency of the pharmacokinetics of 4-hydroxycyclophosphamide was observed. Administration of thioTEPA 1 h prior to cyclophosphamide resulted in decreased Cmax (-62%) and AUC (-26%) values of 4-hydroxycyclophosphamide compared to those of thioTEPA administered 1 h after cyclophosphamide. In human microsomes an inhibition of the conversion of cyclophosphamide to 4-hydroxycyclophosphamide by thioTEPA was observed at clinically relevant concentrations with an IC50 of 23 microM. No inhibition of the formation of TEPA by cyclophosphamide was observed.
ThioTEPA strongly inhibits the bioactivation of cyclophosphamide and this may decrease both efficacy and toxicity. Our results seriously question the practice of the simultaneous continuous infusion of cyclophosphamide and thioTEPA and suggest that the sequencing and scheduling of these two agents in high-dose chemotherapy regimens may be of critical importance. |
Author | TIBBEN, M. M KERBUSCH, T RODENHUIS, S BEIJNEN, J. H HUITEMA, A. D. R |
Author_xml | – sequence: 1 givenname: A. D. R surname: HUITEMA fullname: HUITEMA, A. D. R organization: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, Netherlands – sequence: 2 givenname: T surname: KERBUSCH fullname: KERBUSCH, T organization: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, Netherlands – sequence: 3 givenname: M. M surname: TIBBEN fullname: TIBBEN, M. M organization: Department of Pharmacy and Pharmacology, The Netherlands Cancer Institute Slotervaart Hospital, Louwesweg 6, 1066 EC, Amsterdam, Netherlands – sequence: 4 givenname: S surname: RODENHUIS fullname: RODENHUIS, S organization: Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands – sequence: 5 givenname: J. H surname: BEIJNEN fullname: BEIJNEN, J. H organization: Department of Medical Oncology, The Netherlands Cancer Institute/Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, 1066 CX, Amsterdam, Netherlands |
BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=1457280$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/10972481$$D View this record in MEDLINE/PubMed |
BookMark | eNpV0N9LwzAQB_Agivuhj75KHnytXpu0SX0bY_6AgSJ7H2lyXSNrUptO7H9v5wbqvdzBfTi474ScOu-QkKsYbmMAcRcAEgn7illyQsYxZ0kEkrNTMgbGeZQK4CMyCeF9MDxm7JyMYshFwmU8Jl9vaHa6s95RX1Ld661vKh-aStXWIC2sV8P2U_2IoqddZf1q8Tq7p7q1ndVqSwN-7NBpjAw26Mww9tQ6WtlNFRkfkOoKa99V2Kqmpy1ubI0uXJCzUm0DXh77lKweFqv5U7R8eXyez5aRZpJ3kTIZN6qALM2khBwKwbgRGiSgyHIBKleCS51qyHJdloyZdHgukYKXWc4SNiXR4axufQgtluumtbVq-3UM632A638BDv764JtdUaP5ow-JDeDmCFQYvi9b5bQNv46nYjjHvgG7t3ra |
CODEN | CCPHDZ |
CitedBy_id | crossref_primary_10_2165_00003088_200544110_00003 crossref_primary_10_4143_crt_2005_37_3_137 crossref_primary_10_1097_01_ftd_0000177224_19294_92 crossref_primary_10_1124_dmd_30_5_525 crossref_primary_10_1016_j_bcp_2004_10_008 crossref_primary_10_1038_sj_bmt_1704353 crossref_primary_10_1016_j_tiv_2005_06_049 crossref_primary_10_1016_S1470_2045_04_01528_1 crossref_primary_10_1634_theoncologist_5_5_369 crossref_primary_10_1038_sj_clpt_6100138 crossref_primary_10_1093_annonc_mdf052 crossref_primary_10_2133_dmpk_DMPK_12_RG_014 crossref_primary_10_1016_j_drup_2005_08_003 crossref_primary_10_1016_S0378_4347_01_00178_5 crossref_primary_10_1124_jpet_103_056127 crossref_primary_10_1023_A_1013164013375 crossref_primary_10_1038_sj_tpj_6500157 crossref_primary_10_1097_01_ftd_0000158081_38330_5e crossref_primary_10_1023_A_1023577514605 crossref_primary_10_1038_sj_bjc_6601001 crossref_primary_10_1038_sj_bmt_1703132 crossref_primary_10_1007_s00280_005_1005_4 crossref_primary_10_1080_03602530701836704 crossref_primary_10_1093_annonc_mdf203 crossref_primary_10_1177_0091270006286981 crossref_primary_10_1002_art_20338 crossref_primary_10_1038_sj_bjc_6600631 crossref_primary_10_1080_03602530500364023 crossref_primary_10_1097_FTD_0b013e318194e484 crossref_primary_10_1002_rcm_2110 crossref_primary_10_1007_s00761_007_1240_x crossref_primary_10_1097_00001813_200503000_00013 crossref_primary_10_1111_j_1600_0609_2005_00492_x |
ContentType | Journal Article |
Copyright | 2000 INIST-CNRS |
Copyright_xml | – notice: 2000 INIST-CNRS |
DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION |
DOI | 10.1007/s002800000132 |
DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef |
DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef |
DatabaseTitleList | MEDLINE |
Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
EISSN | 1432-0843 |
EndPage | 127 |
ExternalDocumentID | 10_1007_s002800000132 10972481 1457280 |
Genre | Research Support, Non-U.S. Gov't Journal Article |
GroupedDBID | --- -53 -56 -5G -BR -EM -Y2 -~C .86 .GJ .VR 06C 06D 0R~ 0VY 1N0 1SB 2.D 203 28- 29B 29~ 2J2 2JN 2JY 2KG 2KM 2LR 2P1 2VQ 2~H 30V 36B 3O- 3V. 4.4 406 408 409 40D 40E 53G 5GY 5QI 5RE 5VS 67Z 6NX 6PF 78A 7X7 88E 8AO 8C1 8FI 8FJ 8TC 8UJ 95- 95. 95~ 96X AAAVM AABHQ AABYN AAFGU AAHNG AAIAL AAJKR AAKSU AANXM AANZL AAPBV AARHV AARTL AATVU AAUYE AAWCG AAWTL AAYIU AAYQN AAYTO ABBBX ABBXA ABDZT ABECU ABFGW ABFLS ABFTV ABHLI ABHQN ABIPD ABJOX ABKAS ABKCH ABKTR ABLJU ABMNI ABMQK ABNWP ABPLI ABPTK ABQBU ABSXP ABTEG ABTMW ABULA ABUWG ABUWZ ABXPI ACBMV ACBRV ACBXY ACBYP ACGFS ACHSB ACHVE ACHXU ACIGE ACIPQ ACKNC ACMDZ ACMLO ACOKC ACOMO ACPRK ACTTH ACUDM ACVWB ACWMK ADBBV ADHHG ADHIR ADIMF ADINQ ADJJI ADKNI ADKPE ADMDM ADRFC ADTIX ADURQ ADYFF ADZKW AEBTG AEFIE AEFTE AEGAL AEGNC AEJHL AEJRE AEKMD AENEX AEOHA AEPYU AESTI AETLH AEVTX AEXYK AFDYV AFEXP AFFNX AFJLC AFKRA AFLOW AFQWF AFRAH AFWTZ AFZKB AGAYW AGDGC AGGBP AGGDS AGJBK AGKHE AGMZJ AGQMX AGWIL AGWZB AGYKE AHAVH AHBYD AHIZS AHKAY AHMBA AHSBF AHYZX AIAKS AIIXL AILAN AIMYW AITGF AJBLW AJDOV AJRNO AJZVZ AKMHD AKQUC ALMA_UNASSIGNED_HOLDINGS ALWAN AMKLP AMYLF AMYQR ARMRJ ASPBG AVWKF AXYYD AZFZN B-. BA0 BBAFP BBWZM BDATZ BENPR BGNMA BPHCQ BVXVI CAG COF CS3 CSCUP DL5 DNIVK DU5 EBD EBLON EBS EIOEI EJD EMB EMOBN EN4 ESBYG F5P FEDTE FERAY FFXSO FIGPU FINBP FNLPD FRRFC FSGXE FWDCC FYUFA G-Y G-Z GGCAI GGRSB GJIRD GNWQR GQ6 GQ7 GQ8 GRRUI GXS H13 HF~ HG5 HG6 HMJXF HQYDN HRMNR HVGLF HZ~ I09 IHE IJ- IMOTQ IPNFZ IQODW ITM IXC IZIGR IZQ I~X I~Z J-C J0Z JBSCW JCJTX JZLTJ KDC KOV KOW KPH LAS LLZTM M1P M4Y MA- MK0 N2Q N9A NB0 NDZJH NQJWS NU0 O9- O93 O9G O9I O9J OAM P19 P2P P9S PF0 PQEST PQQKQ PQUKI PROAC PSQYO PT4 PT5 Q2X QOK QOR QOS R4E R89 R9I RHV RIG RNI RNS ROL RPX RRX RSV RZK S16 S1Z S26 S27 S28 S37 S3B SAP SBL SCLPG SDE SDH SDM SHX SISQX SJYHP SNE SNX SOJ SPISZ SRMVM SSLCW SSXJD STPWE SV3 SZ9 SZN T13 T16 TSG TSK TSV TT1 TUC U2A U9L UG4 UKHRP UNUBA UOJIU UTJUX UZXMN VC2 VFIZW W23 W48 WJK WK8 Y6R YLTOR Z45 Z7U Z82 Z83 Z87 Z8O Z8V Z8W Z91 ZGI ZMTXR ZOVNA ~EX ~KM AAEOY AAJBT AASML AATNV ABAKF ABJNI ABTKH ABWNU ACAOD ACDTI ACZOJ ADOXG ADTPH AEEQQ AEFQL AEMSY AESKC AEVLU AFAFS AFBBN AFNRJ AGQEE AGRTI AIGIU AMXSW AOCGG CCPQU CGR CUY CVF DDRTE DPUIP ECM EIF HMCUK IKXTQ IWAJR NPM NPVJJ SNPRN SOHCF AACDK AAYXX ALIPV CITATION |
ID | FETCH-LOGICAL-c384t-ad64dab065688090b734d7c080e76970a9a748c5c069cff33d51092874f69323 |
ISSN | 0344-5704 |
IngestDate | Thu Sep 12 18:46:51 EDT 2024 Thu May 23 23:02:44 EDT 2024 Fri Nov 25 01:07:17 EST 2022 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 2 |
Keywords | Antineoplastic agent Human Drug combination Digestive system Liver Aziridine derivatives Malignant tumor Metabolism In vitro In vivo Alkylating agent Chemotherapy Cyclophosphamide Oxazaphosphinane derivatives Treatment Nitrogen mustard Thiotepa Drug interaction Pharmacokinetics High dose Organic thioamidophosphate |
Language | English |
License | CC BY 4.0 |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c384t-ad64dab065688090b734d7c080e76970a9a748c5c069cff33d51092874f69323 |
PMID | 10972481 |
PageCount | 9 |
ParticipantIDs | crossref_primary_10_1007_s002800000132 pubmed_primary_10972481 pascalfrancis_primary_1457280 |
PublicationCentury | 2000 |
PublicationDate | 2000-00-00 |
PublicationDateYYYYMMDD | 2000-01-01 |
PublicationDate_xml | – year: 2000 text: 2000-00-00 |
PublicationDecade | 2000 |
PublicationPlace | Berlin |
PublicationPlace_xml | – name: Berlin – name: Germany |
PublicationTitle | Cancer chemotherapy and pharmacology |
PublicationTitleAlternate | Cancer Chemother Pharmacol |
PublicationYear | 2000 |
Publisher | Springer |
Publisher_xml | – name: Springer |
SSID | ssj0004133 |
Score | 1.7930815 |
Snippet | Cyclophosphamide and thioTEPA are frequently used simultaneously in high-dose chemotherapy regimens. During a pharmacokinetic study of 31 courses in 20... |
SourceID | crossref pubmed pascalfrancis |
SourceType | Aggregation Database Index Database |
StartPage | 119 |
SubjectTerms | Antineoplastic agents Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics Biological and medical sciences Biotransformation Chemotherapy Cyclophosphamide - administration & dosage Cyclophosphamide - analogs & derivatives Cyclophosphamide - blood Cyclophosphamide - pharmacokinetics Drug Administration Schedule Hematopoietic Stem Cell Transplantation Humans Kinetics Medical sciences Microsomes - metabolism Neoplasms - blood Neoplasms - drug therapy Pharmacology. Drug treatments Thiotepa - administration & dosage Thiotepa - pharmacokinetics Time Factors |
Title | Reduction of cyclophosphamide bioactivation by thioTEPA: critical sequence-dependency in high-dose chemotherapy regimens |
URI | https://www.ncbi.nlm.nih.gov/pubmed/10972481 |
Volume | 46 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LattAFB3cFEqhhDZtU6dNmUXxxpGwpBk9uosdFbfFqXFkyC6MRiMsqC0TO1D3j_qXvTOjpxPoYyOMkGXkc7gv3XsuQh8E0IhR6hiWw2yD8AE1WEKZwYhvxwI8kpXKaeTJpTueky_X9LrT-dXoWrrbxib_-eBcyf-gCucAVzkl-w_IVjeFE_AZ8IUjIAzHv8J4JnVXy5CP7_j3fL3IN-sFW2aJ6MdZLqcWdM1VhZmLLI_CqSqp83LFQdlLbZTrcLmaBJQyxkaimtkXYlmMae36co_DUhQVvlrggIvb9nVKfqBWxa7q9uM5mMrJubJIZv_CrPsVv4az4fxqNG41bkefh8NQNSJMzLpuO_t2EV7Cna7q0m1Ztxjcq1g2LJ1DiEE9vYfYFNoSE8eWorNO01QX1cqskTFru2sVdle7cEvLDdzzDrohZKNeJ6vXGkVptaXCvecdq55Fi1C5yusRemx7kFRKUYJR3U0EsYDexF08SSHnqqY0m7_XCn-erdkGkE71CpW9xEYFONFzdFhkJvhc0-wF6ojVEXoyKXovjlBvqvHcneGoHtrbnOEenjaQfol-VLTEeYr3aYlbtMTxDpe0_IhLUuIHSImzFa5IiZtkwyUpX6HoUxiNxkax4MPgjk-2YBVckrAYomAX3EgwiD2HJJ7UvheeG4ARCZhHfE75wA14mjpOAh4kkBsaUhfyDuc1OljlK_EGYZq66UD4vkshQQCrFPuux6R8H7WJF6eii3rl336z1jIuN5VgdxOfLjptgVJfreHvomMNUuM2gWcT3zr5wzffoqdaxkGW796hg-3tnTiFgHYbv1dU-g1xGKEG |
link.rule.ids | 315,786,790,4043,27956,27957,27958 |
linkProvider | ProQuest |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Reduction+of+cyclophosphamide+bioactivation+by+thioTEPA%3A+critical+sequence-dependency+in+high-dose+chemotherapy+regimens&rft.jtitle=Cancer+chemotherapy+and+pharmacology&rft.au=HUITEMA%2C+A.+D.+R&rft.au=KERBUSCH%2C+T&rft.au=TIBBEN%2C+M.+M&rft.au=RODENHUIS%2C+S&rft.date=2000&rft.pub=Springer&rft.issn=0344-5704&rft.eissn=1432-0843&rft.volume=46&rft.issue=2&rft.spage=119&rft.epage=127&rft_id=info:doi/10.1007%2Fs002800000132&rft.externalDBID=n%2Fa&rft.externalDocID=1457280 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0344-5704&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0344-5704&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0344-5704&client=summon |